|Patient Benefits||Helping to achieve HbA1c targets||Minimise unexplained hypoglycaemia||Lower risk of Glycaemic variation||Injection comfort and adherence|
The consequences of unexplained hypoglycaemia can be severe, impacting patients, family and friends, healthcare workers, the healthcare system and the wider health economy. In an article published in the British Journal of Diabetes & Vascular Disease in 20111, Frier et al. highlighted the morbity associated with diabetes related hypoglycaemia :
“This survey supports previous studies in demonstrating that severe hypoglycaemia involves a major cost burden on healthcare systems. This includes direct costs for hospitals, emergency departments, emergency ambulance services and primary care services”.
“Direct costs are especially high for the minority of episodes that result in hospital admission, but substantial costs are also generated by calling out emergency ambulance or primary care services which accounts for a higher absolute number of severe hypoglycaemic events”.
“Measures designed to reduce the overall incidence of severe hypoglycaemic events have the potential to save considerable healthcare costs, while greatly improving the quality of life of patients with both type 1 and type 2 diabetes”.
Frier et al.1 defined Severe Hypoglycaemia Event (SHE) as needing third party assistance. In his study in the UK, he found that:
By extrapolating data for Tayside, a healthcare region within the UK, Frier1 estimated that SHE costs Healthcare Service ≤£13 million per year
According to Hammer2, SHE treatment adds significantly to healthcare costs. Average costs were lower for T1DM than T2DM in all three countries
Average SHE treatment costs for T2DM
Average SHE treatment costs for T1DM
Clinical base-line characteristics and medical history:
Outcome after optimal injection technique intervention:
Complete the FITTER journey by scrolling down the page.
Click on the circles for more information.